Skip to content
Screener

LivaNova LIVN Business Combination, Contingent Consideration, Liability

Business Combination, Contingent Consideration, Liability at other companies

Boston Scientific logo
Boston ScientificBSX

Other financials

Income statement

See full
Revenue$390.6M+10.8%
Gross profit$273.7M+14.5%
Operating income$49.5M-8.7%
Net income$108.6M+300%
EPS (diluted)$1.93+286%

Balance sheet

See full
Cash & equivalents$516.6M-13.0%
Total debt$348.5M-27.8%
Total equity$1.3B+18.0%
Total assets$2.6B+5.4%

Cash flow

See full
Operating cash flow$66.6M+5.8%
CapEx$31.6M+108%
Free cash flow$35.0M-26.7%

Valuation

See full
Market cap$4.17B+61.5%
Enterprise value$4.01B+61.9%
P/E22.6×-67.9×
P/S2.8×+0.9×

Profitability

See full
Gross margin68.1%+0.1pp
Operating margin12.7%-0.7pp
Net margin-16.1%-18.0pp
FCF margin10.1%-2.3pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.2×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiability.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001639691-26-000090
June 30, 2026TotalFair Value Measurements Using Inputs Considered as: / Level 1Fair Value Measurements Using Inputs Considered as: / Level 2Fair Value Measurements Using Inputs Considered as: / Level 3
Derivative assets - 2029 Capped Calls57,29357,293
Investment in convertible notes receivable3,0003,000
$60,818$525$60,293
Liabilities:
Derivative liabilities - freestanding instruments (FX)$61$61
Derivative liabilities - 2029 Embedded Derivative152,904152,904
ImThera contingent consideration arrangements42,12142,121
$195,086$61$195,025

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's business combination, contingent consideration, liability?
LivaNova (LIVN) reported business combination, contingent consideration, liability of $42.12M in Q2 2026.
What is the long-term trend for LivaNova's business combination, contingent consideration, liability?
Over 5 years (2020 to 2025), LivaNova's business combination, contingent consideration, liability has grown at a 0.5% compound annual growth rate (CAGR), from $89.85M to $92.08M.
What does business combination, contingent consideration, liability mean?
Business Combination, Contingent Consideration, Liability

Ask your AI about LivaNova's business combination, contingent consideration, liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude